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Resumo 
Nos últimos anos, tem-se assistido a um aumento da incidência de infeções fúngicas invasivas, 
particularmente as que são causadas por Candida spp., sendo estas frequentemente resistentes ao 
fluconazol e a outros azóis. O número de antifúngicos disponíveis é limitado, e além disso, embora 
existam já antifúngicos eficazes contra alguns fungos, a resistência intrínseca ou adquirida, exibida 
por alguns deles, obriga ao desenvolvimento de novos compostos com atividade antifúngica ou que 
sejam capazes de inibir alguns mecanismos de resistência. A resistência de Candida albicans aos 
azóis deve-se, muitas vezes, à reduzida acumulação dos fármacos no interior das células fúngicas 
devido ao efluxo ativo dos mesmos por bombas de efluxo. 
Assim sendo, ao longo deste trabalho de investigação foi testada uma pequena biblioteca de 
compostos orgânicos naturais e sintéticos – chalconas e xantonas – para avaliar o seu potencial quer 
como antifúngicos, quer como inibidores das bombas de efluxo. Dos 15 compostos testados 
inicialmente, nenhum apresentou um valor de concentração mínima inibitória (MIC) relevante, 
sendo sempre superior ao que é observado com fluconazol. Assim, dos compostos testados, nenhum 
foi considerado como potencial antifúngico a desenvolver para o tratamento de micoses. Por outro 
lado, em termos de inibição das bombas de efluxo, dos 8 compostos testados, apenas a utilização de 
amiodarona em combinação com o fluconazol, a pH 5.0, apresentou valores de MIC muito inferiores 
aos obtidos com a utilização do fluconazol isoladamente. 
Palavras-chave: Antifúngicos; Inibidores de Bombas de Efluxo; Fluconazol; Mecanismos 
de Resistência. 
Abstract 
In the last years, it has seen an increase in the incidence of invasive fungal infections, 
particularly caused by Candida spp., which are frequently resistant to fluconazole and others azoles. 
There are a limited number of antifungals available, and moreover, the intrinsic or acquired 
resistance exhibited by some of these fungi requires the development of new compounds with 
antifungal activity or those which are able to inhibit the mechanisms of resistance. Manifold 
mechanisms of azole resistance in Candida albicans including reduced accumulation of the drugs 
through active efflux by efflux pumps. 
Therefore, throughout this work research, a small library of natural and synthetic compounds 
was tested, to assess their potential as antifungals or as efflux pump inhibitors (EPIs). From 15 
compounds tested, none of them showed a minimum inhibitory concentration (MIC) relevant, and 
always higher than that observed with fluconazole. Therefore, none of these compounds were 
considered with antifungal potential to develop for the mycoses treatment. On the other hand, related 
to the efflux pump inhibition, from 8 compounds tested, only the use of amiodarone in combination 
with fluconazole, pH 5.0, exhibited a significant decrease in MICs. 
Key words: Antifungals; Efflux Pump Inhibitors; Fluconazole; Mechanisms of Resistance. 
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Outline of the Dissertation 
 The present dissertation is organized in five main parts: 
 
Chapter I. - Introduction 
In this chapter, a brief introduction of some key concepts about mycoses, the main 
microorganisms responsible for these diseases, as well as the therapy that is currently used. 
A brief description of the mechanisms of resistance to antifungals and possible ways to 
overcoming these mechanisms. In this chapter, it is also addressed the chemistry of 
xanthones and chalcones as well as their importance in Medicinal Chemistry. 
 
Chapter II - Material and Methods 
In this chapter it is explained the methods and techniques used throughout this work. 
 
Chapter III – Results and Discussion 
Here are presented all the results obtained and the discussion about them, as well as 
the explanation of the reasons why it may have occurred. 
 
Chapter IV – Conclusion and Future Work 
In this chapter it is done a consideration about the dissertation and the relevance of 
the issue addressed. It is also proposed some interesting new and different ideas and 
techniques to explore the results already obtained and to get better results and explanations. 
 
Chapter V - References 
It is described all the references that were used along this work, which were obtained 
from: PubChem (Open Chemistry Database), PubMed, Science Direct and EBSCO. All the 
chemical structures were designed by using ChemBioDraw®. 
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Chapter I 
Introduction 
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Introduction 
Infectious diseases represent one of the most important challenges due to the very 
high levels of morbidity and mortality they cause1. At the beginning of 20th century, bacterial 
infections were the most important cause of mortality, but around 1950s, when antibiotic 
therapies and cancer treatment were developed, a severe rise in fungal infections was 
observed2-3. Nowadays, treating human infectious diseases remain as a colossal health 
problem1, despite the advances in clinical medical mycology since the beginning of 21st 
century3. 
Fungal infections are caused by two main types of microorganisms, primary or 
opportunistic pathogens. Primary pathogens are those which are able to establish an 
infection in the healthy immunocompetent individuals. In contrast, opportunistic 
pathogens, among them commensal microorganisms, are able to develop infectious 
colonization of the human body when particular criteria, undermentioned, exists2. 
Fungal pathogens can be divided into two main groups, filamentous fungi and yeasts. 
Filamentous fungi are formed by cylindrical and filamentous cells called hyphae, and a mass 
of hyphae is termed a mycelium. Yeasts are the simplest fungi and they are unicellular3. 
Most of the primary pathogens are filamentous fungi, while most of the opportunistic 
pathogens are yeasts and some species of filamentous fungi. Fungal infections can be also 
classified according to the tissue infected (Table 1). Superficial mycoses are limited to the 
most external part of the skin and hair; cutaneous mycoses, caused by dermatophytes, affect 
keratinized structures of the body, subcutaneous mycoses are caused by implantation of 
spores when, for example, occurs a puncture; mucosal infections are mostly caused by 
opportunistic yeasts, and systemic mycoses may involve any part of the body3. This last type 
of fungal infection with symptoms ranging from a simple fever to a severe and rapid septic 
shock, is very common in immunocompromised patients and is frequently associated with 
an elevated mortality rate2. Candida albicans, Cryptococcus neoformans, and Aspergillus 
fumigatus are the most common causes of invasive fungal infections4, such as disseminated 
candidiasis, cryptococcal meningitis and invasive aspergillosis3, 5. 
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Table 1 – Classification of mycoses based on the primary site of pathology2-3 
Body Location Pathogen Type Organ Associated Genus 
Superficial Primary Skin and Hair Malassezia 
Cutaneous Primary Skin, Hair and Nails 
Trichophyton 
Epidermophyton 
Microsporum 
Mucosal Opportunistic 
Digestive Tract, Eye, 
Urinary Tract and 
Vagina 
Candida 
Systemic Opportunistic Any organ 
Candida 
Aspergillus 
Cryptococcus 
 
 
Candida albicans is a normal commensal of human mucosal surfaces and one of the 
most frequently observed opportunistic human fungal pathogen causing mucosal and 
systemic infections in individuals with compromised immune defenses6-8. Other non-
albicans Candida species associated with biofilm formation and device-related infections 
include C. glabrata and C. parapsilosis. These types of infections can be superficial and 
affect the skin or mucous membranes, or can be disseminated by blood circulation with 
consequences. Therefore, systemic fungal infections are hard to diagnose, difficult to treat 
and may require both long-term antifungal therapy and the physical removal of the device 
to control the infection9, contributing to their high morbidity and mortality8. 
In the last years, it has seen an increase in the incidence of invasive fungal infections, 
particularly caused by Candida spp., which are frequently resistant to fluconazole (FLC) 
and others azoles7, 10-12. Nowadays, invasive mycoses represent an exponentially growing 
threat due the difficult diagnosis and unavailability of effective antifungal drugs13. 
Paradoxically, medical progress has led to an expanding population of susceptible 
hosts with impaired immunological defenses against infection in the community and 
hospitals14. The use of broad-spectrum antibiotics, parenteral nutrition, indwelling 
catheters, the presence of immunosuppression, or disruption of mucosal barriers due to 
surgery, radiotherapy and chemotherapy, are among the most important predisposing 
factors for invasive fungal infection9, 12. 
The increasing resistance of pathogenic fungi to antifungal compounds and the 
reduced number of available drugs led to the search for therapeutic alternatives, also among 
natural products, including xanthones and chalcones15. Therefore, permanent drug 
discovery and research programs are still required1. 
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Antifungal agents available 
An ideal antifungal agent should be active and highly selective against a fungal-
specific target, fungicidal rather than fungistatic due to its mechanism of action, with 
suitable ADME properties – absorption, distribution, metabolism and excretion – and 
proper for formulation by both oral and intravenous route16. 
There are a limited number of antifungals available, most of them only provide 
fungistatic but not fungicidal effects6 (Table 2). Similarly, there are relatively few agents that 
can act only on targets not shared with human hosts, such as fungal cell wall because this is 
not present in human cells17. 
Table 2 – Topical and systemically active antifungal agents3 
Antifungals Target Site 
Allylamines Terbinafine 
Ergosterol biosynthesis – 
squalene epoxidase 
Azoles 
Fluconazole, Itraconazole, 
Voriconazole, Posaconazole, 
Ketoconazole 
Ergosterol biosynthesis – 1-4-
α-demethylase 
Echinocandins Caspofungin, Anidulafungin, 
Micafungin 
β-(1,3)-glucans synthesis in 
cell wall 
Fluorinated 
Pyrimidine 5-Fluorocytosine 
DNA, RNA and protein 
synthesis 
Polyenes Amphotericin B (lipid formulations) 
and Nystatin 
Ergosterol in cell membrane 
 
 
 
Allylamines 
The class of allylamines acts by inhibition of the squalene epoxidase enzyme, resulting 
in a decrease in ergosterol and an increase in squalene concentration within the fungal cell 
membrane, damaging it3, 18. Squalene epoxidase is an enzyme of the ergosterol biosynthetic 
pathway that catalyzes the epoxidation of squalene to 2,3-oxidosqualene in fungi19. 
Terbinafine (Fig. 1, C21H15N) is an example of this class of antifungals, being a lipophilic 
agent that accumulates in skin, nails and fat tissues, from which is slowly released. It is an 
active agent in oral and topical formulations3, and it has shown promise for the treatment 
of infections caused by FLC-resistant Candida strains when used in combination with 
FLC18. 
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Figure 1 - Chemical structure of terbinafine 
 
 
 
Azoles 
Several azoles, which act by the inhibition of the enzyme lanosterol 14-α-demethylase, 
important to ergosterol biosynthesis pathway (Fig. 2), were widely used to treat Candida 
infections18, 20. 
 
 
Figure 2 - Ergosterol biosynthetic pathway in fungi3, 12, 21 
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Ergosterol is a necessary sterol, important for maintaining the structural integrity of 
the fungal cell membrane. Inhibition of lanosterol 14-α-demethylase leads to depletion of 
ergosterol, which cause the formation of membranes with altered structure and function, 
and accumulation of sterol precursors12, which can lead to the destruction of the fungal cell. 
The azole class of antifungal agents can be divided based on the structure into 
imidazoles – two nitrogens in the azole ring – and triazoles – three nitrogens in the azole 
ring. 
Among the imidazoles, the only antifungal agent used systemically is ketoconazole 
(Fig. 3, C26H28Cl2N4O4). 
 
 
Figure 3 - Chemical structure of ketoconazole 
 
 
The triazoles have systemic activity and include fluconazole (Fig. 4, C13H12F2N6O), 
itraconazole (Fig. 5, C35H38Cl2N8O4), voriconazole (Fig. 6, C16H14F3N5O), and posaconazole 
(Fig. 7, C37H42F2N8O4)18. 
 
 
 
Figure 4 – Chemical structure of fluconazole 
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FLC is one of the most widely used antifungal agents, both for prophylaxis and therapy 
of Candida infection6, 11. The azole used as standard throughout this work was FLC, a first 
generation triazole with good oral bioavailability and low toxicity. This is a water-soluble 
agent and may be administered orally or intravenously, it has low protein binding and it is 
distributed to all organs and tissues, including the central nervous system18. 
 
 
 
Figure 5 - Chemical structure of itraconazole 
 
 
 
 
Figure 6 - Chemical structure of voriconazole 
 
 
 
 
Figure 7 - Chemical structure of posaconazole 
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Isavuconazole (Fig. 8, C22H17F2N5OS) and albaconazole (Fig. 9, C20H16ClF2N5O2) are 
recent azoles, undergoing clinical trials22-23. 
 
 
Figure 8 - Chemical structure of isavuconazole 
 
 
 
Figure 9 - Chemical structure of albaconazole 
 
 
Echinocandins 
Echinocandins are a high selective class of semisynthetic lipopeptides and its 
mechanism of action consists on non-competitive inhibition of synthesis of β-(1,3)-glucans, 
which are important constituents of the fungal cell wall. Since mammalian cells do not 
contain these constituents, this class of antifungal agents is selective and toxic only to fungi4. 
The glucans play an important role in maintenance of the osmotic integrity of the fungal 
cell, and are also needed to cell division and cell growth18. The first licensed echinocandin 
was caspofungin in 2001, followed by micafungin in 2005, and anidulafungin in 20064. 
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Caspofungin (Fig. 10, C52H88N10O15) is a water-soluble amphipathic lipopeptide with 
a molecular mass of 1213 kDa, being a semisynthetic derivative of the fermentation product 
of Glarea lozoyensis3, 24. 
 
Figure 10 - Chemical structure of caspofungin 
 
Micafungin (Fig. 11, C56H71N9O23S) is a promising echinocandin, a water-soluble 
antifungal agent which is derived from Coleoptioma empedri, a natural product of the fungi 
via enzymatic cleavage of a hexapeptide. The addition of a fatty N-acyl side chain improves 
its antifungal activity25. According to Barrett, 2002, and Mikamo, 2000, bearing a fatty acid 
acyl group on the N-terminal moiety lead to excellent water solubility by virtue of the 
presence of a sulfonate moiety on the homotyrosine residue. This molecular modification 
displayed more potent inhibition of β-1,3-glucan synthase from C. albicans26-27. 
 
Figure 11 - Chemical structure of micafungin 
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Anidulafungin (Fig.12, C58H73N7O17) is a semisynthetic product from fermentation of 
Aspergillus nidulans3. 
 
Figure 12 – Chemical structure of anidulafungin 
 
 
 
Fluorinated Pyrimidine 
5-Fluorocytosine (Fig.13, C4H4FN3O) is the only available antifungal agent that acts 
as an antimetabolite. This molecule interferes with the DNA, RNA and protein synthesis in 
the fungal cell because it is a fluorinated pyrimidine analogue. This synthetic compound is 
water soluble and has an excellent bioavailability when administered orally. To avoid 
toxicity, it is important to monitoring serum concentrations of 5-fluorocytosine, because it 
can achieve high and toxic concentrations in the blood18. 
 
 
 
Figure 13 - Chemical structure of 5-fluorocytosine 
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Polyenes 
Amphotericin B (AmB) and nystatin are examples of polyenes used in current therapy. 
AmB is a natural product from Streptomyces nodosus3, and chemically, it is a heptaene –
contains seven conjugated double bonds – which may be inactivated by extreme values of 
pH, heat and light18. The antifungal activity of AmB (Fig. 14, C47H73NO17) involves the 
binding of this molecule to ergosterol, producing ion channels that destroy the integrity of 
the fungal cell membrane, and lead to damage on intracellular constituents and cell death. 
The selective toxicity for fungal cells exhibited by this drug, is due to the fact that AmB is 
more effective in permeabilizing fungal cell membranes with ergosterol than mammalian 
membranes with cholesterol28. AmB is also able to bind to cholesterol but with lower 
affinity18. This could be explained by the conformational difference between the cylindrical 
three-dimensional structure of the ergosterol and the sigmoid shape of the cholesterol. Due 
to the AmB molecular structure, there is higher affinity for the binding site with the 
ergosterol. However, this selectivity is low and suggests that AmB may have potential 
toxicity for mammalian cells, as could be seen in nephrotoxicity situations that occur with 
the use of this molecule3. AmB may also act by the generation of several oxidative reactions 
with formation of toxic free radicals21. Currently, there are AmB lipidic formulations more 
stable and soluble, with increased absorption and that allow to reduce the side effects, such 
as the nephrotoxicity aforementioned. These formulations are administered by intravenous 
route3, 18. Nevertheless, these have much higher associated costs, continuing to be used the 
traditional AmB formulations at hospitals of some countries. 
 
 
Figure 14 - Chemical structure of amphotericin B 
 
 
Nystatin (Fig. 15, C47H75NO17) is a polyene, currently used as a topical agent, 
considering the high toxicity when administered by systemic route. Nevertheless, this 
molecule is also being developed in a liposomal formulation for systemic use29. 
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Figure 15 - Chemical structure of nystatin 
 
 
Mechanisms of resistance to antifungals 
For nearly 30 years, AmB was the sole drug available for the treatment of invasive 
fungal infections. Although AmB exhibited superior clinical effectiveness in the treatment 
of systemic candidiasis, its narrow therapeutic index and significant nephrotoxicity has 
limited its utility. The emergence of imidazoles and triazoles in the early 1990s was an 
important step to advance with the safe and effective treatment of local and systemic fungal 
infections. The high safety profile of the triazoles, particularly the FLC, its good 
bioavailability and clinical effectiveness, led to their extensive therapeutic and prophylactic 
use12. Although azole derivatives are the most widely used antifungal agents because of their 
high therapeutic index, they are fungistatic and not fungicidal against pathogenic yeasts, 
which leads to resistance to azoles in prolonged infections4,12. 
Nowadays, despite some antifungal agents being efficacious against some fungi, 
particularly the echinocandins and liposomal AmB formulations, and beyond the toxicity to 
the host, the intrinsic resistance exhibited by some of these fungi has led the researchers to 
detailed investigation. So, it is fundamental to find and to develop new compounds with 
some antifungal activity, or those which are able to inhibit some of the mechanisms of 
antifungal resistance9, 30. These mechanisms, some of them enumerated in Table 3, are 
complex and it can occur in response to a compound or an irreversible genetic change, 
including alterations or overexpression of target molecules, active extrusion through efflux 
pumps and tolerance, which are all characterized mechanisms utilized by fungi to resist to 
the antifungal treatment9. 
There has been a documented increase in fluconazole resistance among species of 
Candida, including C. albicans, C. lusitaniae, C. tropicalis and C. dubliniensis, which has 
been attributed to the use of fluconazole as empirical antifungal therapy since the 1990s31-
32. 
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As mentioned in Table 3, manifold mechanisms of azole resistance in C. albicans, 
including reduced accumulation of the drugs through active efflux (overexpression of genes 
CDR1, CDR2 and MDR1), and alteration or overexpression of the target enzyme, have 
already been described6-7. 
Table 3 – Genetic mechanism of resistance in Candida spp.14 
Decreased drug  concentration 
(efflux pumps) 
↑ CDR gene of ATP binding cassete (for all azoles) 
↑ MDR gene of major facilitator class (for fluconazole) 
C. albicans CDR1, CDR2, MDR1 
C. glabrata CgCDR1, PDH1, Snq2 
Target cell alteration 
Mutation of ERG11 
↑ ERG11p 
Chromosomal aneuploidy or 
isochromosome Chromosome 5 in C. albicans 
  
 
 
Efflux pumps in resistance to azoles 
The main molecular mechanism leading to high-level azole resistance in C. albicans 
is the efflux of drug mediated by the ATP-binding cassete (ABC) and the major facilitator 
superfamily (MFS) transporters7, 9, 13, 32. 
The ABC transporters use the energy from ATP hydrolysis to pump substrates out of 
the cell20 (Fig. 16). This type of transporter is generally made up of two transmembrane 
domains (TMDs) and two cytoplasmic located nucleotide binding domains (NBDs). The 
TMDs comprise α-helices of 12 transmembrane segments (TMS), while the NBDs have α-
helices and β-sheets. All this structure alone is probably not enough for substrate transport 
across the membrane bilayer, once the transport of these substrates requires energy from 
the hydrolysis of the ATP carried out at the NBDs33. 
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Figure 16 – Representation of ABC transporters of Candidaa 
 
The MFS transports substrates across a membrane in exchange for H+ ions20 (Fig.17). 
This class of major drug transporters was originally defined as a superfamily of permeases 
that are characterized by two structural units of six TMS α-helical segments, linked by a 
cytoplasmic loop33. Multiple antifungal agents can be substrates for these transporters, and 
thus, their overexpression can lead to cross-resistance among different drugs, particularly 
azoles9. 
 
Figure 17 – Representation of MFS transporters of Candidaa 
 
The first multidrug efflux pump identified in a fungal pathogen was MDR1 from C. 
albicans, which belongs to the MFS. A recent report showed that strong overexpression of 
MDR1 in C. albicans resulted in increased resistance of the cells to compounds that are 
                                                        
a Figures 16 and 17 were based on figures from Prasad et al., 2006 
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supposed to be substrates of this efflux pump, confirming that MDR1 can mediate multidrug 
resistance (MDR) in C. albicans5. Similarly, the first described ABC transporter of a 
pathogenic fungus was also from C. albicans. The CDR1 was found to confer cross-
resistance to many structurally unrelated drugs, including various azoles5, 34.  
In C. albicans, both the ABC transporter genes CDR1 and CDR2 and the MFS gene 
MDR1 can be upregulated, although not simultaneously, indicating the existence of separate 
regulatory pathways for the two transporter classes. Regulators of these transporters, TAC1 
and MRR1, which control the overexpression of C. albicans CDR1/CDR2 and MDR1, 
respectively, have been identified. Mutations in these transcription factors are responsible 
for the overexpression of these transporters in clinical isolates34. 
Candida glabrata is a species that exhibits high intrinsic resistance to fluconazole, 
but its resistance can increase during FLC therapy5. In C. glabrata, increased levels of 
expression of the ABC transporters genes CgCDR1 and CgCDR2 have been also shown in 
azole-resistant isolates of C. glabrata. There is a genetic evidence supporting the role of 
multidrug transporters in the azole resistance of C. glabrata, similarly to C. albicans35. 
Candida krusei is intrinsically resistant to FLC, due to the low affinity of its sterol 14α-
demethylase for this drug, and can acquire resistance to other azoles by reduced 
intracellular drug accumulation5. 
 
 
Modification of the ERG11 at molecular level 
The fungal target of azole antifungals is a cytochrome P450 enzyme (encoded by 
ERG11) involved in 14-α-demethylation of lanosterol14, 34. Another azole resistance 
mechanism involves alteration of the target enzyme by amino acid substitutions caused by 
mutations in ERG1134. 
Some studies showed a decrease in fluconazole susceptibility, and by comparison of 
the DNA sequences of ERG11 from azole-resistant isolates and sensitive C. albicans strains, 
it revealed a point mutation (R467K) that results in the replacement of arginine (R) for 
lysine (K) at position 467. It has been suggested that this mutation causes structural or 
functional changes in the heme cofactor of the enzyme. Preliminary studies indicate that 
R467K by itself can confer azole resistance by decreasing the affinity of the enzyme for 
fluconazole12. Overexpression of ERG11 has also been documented but its contribution to 
azole resistance still is not clear12. 
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Chromosomal aneuploidy or isochromosome 
In C. albicans the only mechanism of gene amplification leading to azole resistance is 
the formation of aneuploidy or isochromosome. The chromosome arm bearing both 
transcription factor, regulating ABC transporter, and target of the azoles ERG11 is 
duplicated14  
 
 
 
Antifungal resistance inhibition 
Besides meeting pharmacological requirements, an ideal antifungal agent would not 
be susceptible to the development of resistance due to efflux mechanisms8, or others. 
Several approaches have been proposed to block efflux-mediated antifungal drug 
resistance, including (1) the use of alternative antifungal drugs that are not efflux pump 
substrates (e.g. echinocandins and polyenes); protecting the efficacy of antifungals that are 
subject to efflux by developing treatments that prevent efflux, such as (2) give a drug in 
combination with a efflux pump inhibitor (EPI) or (3) use a drug that is a multifunctional 
inhibitor, affecting target, efflux pump activity, and efflux pump transcription; (4) deplete 
cells of energy required for drug efflux pump by inhibiting the plasma membrane H+ 
ATPase; (5) design drugs with an enhanced rate of uptake and thus shift the balance 
between uptake and efflux, so that a high intracellular concentration of the drug in 
maintained, despite any upregulation of efflux8, 13 (Fig. 18). 
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Figure 18 - Possible ways to overcoming efflux-mediated fungal drug resistanceb 
 
 
Thus, finding and developing new modulators that can block the efflux pumps, 
increasing the intracellular concentration of the antifungal drugs and reverting resistance, 
may be an innovative pharmaceutical strategy6, 11. The compounds used throughout this 
work can provide a great resource of antimicrobial activity or inhibition of the mechanisms 
of resistance. 
 
 
Small library of natural and synthetic compounds 
Plants produce an enormous array of secondary metabolites, and it is commonly 
accepted that a significant part of this chemical diversity helps to protect plants against 
microbial pathogens36. Therefore, xanthones and chalcones have been showed a potential 
as antifungals, as described in several work researches1, 15, 37-38. Antifungal agents based on 
xanthones and chalcones have important advantages such as the availability as natural 
compounds or the possibility to be synthesized easily and the potential to interact with some 
important targets in microorganisms. These compounds could consequently serve as a 
novel generation of antimicrobial agents as a strategy for responding to outbreaks of 
resistant fungal infections1. 
                                                        
b The scheme (Fig.18) was adapted from Cannon et al., 2009 and Prates et al., 2011 
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Xanthones (Fig.19) are three ring oxygenated compounds which are mainly found as 
secondary metabolites in plants and microorganisms, with a large spectrum of biological 
and pharmacological activities38-39. The interest in these compounds is related with their 
structural scaffold and pharmacological importance, attracting many scientists to isolate or 
synthetize xanthone derivatives as an alternative to synthetic antifungal drugs15, 39. Many of 
them have proved to be important building blocks for the synthesis of new interesting 
compounds40. 
 
 
Figure 19 – Basic chemical scaffold of xanthones 
 
Chalcones (Fig. 20) are intermediate precursors to all flavonoid compounds, and 
some of them have been reported for their growth inhibitory effect on human tumor cell 
lines37. It was decided to test such compounds in bacterial and fungal cells because, as 
eukaryotic cells, it could also affect their development. 
 
 
Figure 20 - Basic chemical scaffold of chalcones 
 
  
19 
Once efflux pump inhibitor (EPI)/antimicrobial combination drug should exhibit 
increased potency, enhanced spectrum of activity and reduced propensity for acquired 
resistance41, three known EPIs (verapamil - VRP, amiodarone – AMD, and sodium azide - 
AZD) were used to first understand their mechanism of action and, thereby, it was possible 
to find a model to then test xanthones and chalcones. 
Verapamil (Fig.21, C27H39ClN2O4), a known EPI, is widely used in the treatment of 
hypertension and angina pectoris and belongs to the phenylalkylamine class of calcium 
channel blockers42. As calcium channel blocker, it was decided to test this compound for 
inhibition of the efflux pump mechanism. 
 
 
 
Figure 21 – Chemical structure of verapamil hydrochloride 
 
 
 
Amiodarone (Fig.22, C25H29I2NO3) is an iodine benzo furan derivative that belongs to 
class III antiarrhythmic agents. It is wide used in the treatment of cardiac tachyarrhythmia 
due its capacity to block calcium, potassium and sodium channels. AMD is one promising 
new antifungal, once it has shown fungicidal activity against yeasts and other clinically 
important fungi. Furthermore, low doses of AMD have been reported to be synergistic with 
different azoles in resistant Aspergillus fumigatus strains. In C. albicans, it can be inferred 
that AMD induce calcium stress and modify the calcineurin pathway regulation, changing 
the tolerance to antifungal agents, cation homeostasis and virulence43. 
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Figure 22 - Chemical structure of amiodarone 
 
 
Sodium azide (Fig.23, N3Na) was used to search FLC resistance by efflux pumps. This 
respiratory chain inhibitor decreases the energy potential of the cells and, consequently, 
block the efflux pumps depending on energy6, 32. 
 
 
 
Figure 23 - Chemical structure of sodium azide 
 
 
 
Thioxanthones are S-heterocycles with a dibenzo-γ-thiopyrone scaffold and they have 
interesting and important biological activities. The aminated thioxanthones derivatives, 
used in this work research, have dual activity as antitumor agents and P-glycoprotein (P-
gp) inhibitors. The amine is described as an important pharmacophoric feature for P-gp 
inhibition. P-gp is a known efflux pump, from ABC super-family, that actively extrudes 
several structurally unrelated compounds out of the cells44. Therefore, thioxanthones were 
used to assess their potential as EPI. 
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Material and Methods 
Throughout this work, was screened a small library of 23 compounds to evaluate their 
potential antimicrobial activity, as well as to assay some potential EPIs in the reversion of 
resistance of strains of Candida spp. to azoles. 
Xanthones and chalcones were used, in first place, to assess either the antifungal as 
the antibacterial activity. 
 
Evaluating the antifungal activity of xanthones and chalcones 
Library of natural and synthetic compounds 
All the xanthones (Fig. 24-33) and chalcones (Fig. 34-38) tested were kindly provided 
by CEQUIMED-UP and were obtained in house. The chiral derivatives of xanthones tested 
throughout this work (Appendix A), were synthetized by coupling a carboxyxanthone or a 
carboxymethoxyxanthone with both enantiomers of commercially available chiral building 
blocks – amino alcohols, amines and amino esters38. Their structure elucidation was 
established by 1H and 13C NMR techniques38. 
These compounds were diluted in dimethyl sulfoxide (DMSO). 
 
Xanthones 
 
 
 
Figure 24 – Chemical structure of X2ADF-RS 
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Figure 25 – Chemical structure of X2ADF-SR 
 
 
 
 
 
 
Figure 26 – Chemical structure of XEVOL-L 
 
 
 
 
 
 
Figure 27 – Chemical structure of XEVOL-D 
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Figure 28 – Chemical structure of XEGOL-1D 
 
 
 
 
 
Figure 29 – Chemical structure of XEGOL-1L 
 
 
 
Figure 30 – Chemical structure of XEGOL-2D  
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Figure 31 – Chemical structure of XEGOL-2L 
 
 
 
 
 
 
Figure 32 – Chemical structure of XEA-1S 
 
 
 
 
 
 
Figure 33 – Chemical structure of XEA-1R 
 
 
 
Chalcones 
Chalcones (Fig. 34-38) were prepared by base-catalyzed aldol condensation of 
properly substituted acetophenones and benzaldehydes under microwaves (MW) 
irradiation. Their structure elucidation was established by 1H and 13C NMR techniques37. 
 
26 
 
 
 
Figure 34 – Chemical structure of PB3 
 
 
 
 
Figure 35 – Chemical structure of PB4 
 
 
 
Figure 36 – Chemical structure of PB6 
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Figure 37 – Chemical structure of PB16 
 
 
 
 
Figure 38 – Chemical structure of PB17 
 
 
 
Microorganisms and media 
In this work, the antifungal activity of compounds was evaluated against a yeast 
(Candida albicans), a filamentous fungus (Aspergillus fumigatus), and a dermatophyte 
(Trichophyton rubrum). The microorganisms were sub-cultured on Sabouraud dextrose 
agar before use, to ensure purity and viability. 
RPMI 1640 medium, with L-glutamate but without sodium bicarbonate (Biochrom), 
was supplemented with 3-(N-morpholino)-propanesulfonic acid (MOPS, Sigma Life 
Science), and pH was adjusted to 7.0 ± 0.2 (Appendix B). Minimum inhibitory 
concentrations (MICs) were obtained for all the microorganisms, according to the National 
Committee for Clinical Laboratory Standards Institute M27-A3, M27-S3 and M38-A2 
protocols45-47. 
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Antifungal susceptibility testing by broth microdilution45-47 
All the aforementioned compounds were dissolved in DMSO, initial concentration of 
25.6 mg/mL, diluted in RPMI 1640 and tested from 1024 µg/mL to 128 µg/mL on plates. 
First of all, to evaluate the susceptibility of the microorganisms to the compounds, an 
assay in 96-well microtiter plates were performed. Sterility control (SC) received only 200 
µL of RPMI 1640. A 100 µL volume of RMPI 1640 containing a twofold concentration of 
each compound tested, was added to a series of wells. Cultures were suspended in 2 mL of 
sterile 0.145 mol/L saline (8.5 g/L NaCl; 0.85% saline). The suspension was vortexed for 15 
seconds and the cell density was adjusted with a spectrophotometer by adding sufficient 
sterile saline to increase the transmittance to that produced by a 0.5 McFarland standard at 
530 nm wavelength. This procedure has yielded a yeast stock suspension of 1 x 106 to 5 x 106 
cells/mL. A working suspension was made by 1:50 dilution followed by a 1:20 dilution of 
the stock suspension in RPMI 1640 to obtain the twofold inoculum concentration (1 x 103 
to 5 x 103 CFU/mL). 100 µL of this suspension (1:1 dilution) was added to each well to give 
a final inoculum density of 0.5 x 103 to 2.5 x 103 CFU/mL and the final concentration of the 
compound. For filamentous fungi and dermatophytes, the spore suspension was prepared 
in approximately 1 mL of sterile 0.85% saline added of one drop (approximately 0.01 mL) 
of Tween 20 to facilitate the spore separation. The cell density was adjusted by spores 
counting at approximately 0.4 x 104 to 5 x 104 CFU/mL for Aspergillus spp. and 1 x 103 to 3 
x 103 CFU/mL for dermatophytes. The growth control (GC) was prepared with 100 µL of 
RPMI 1640 with 2% DMSO and 100 µL of the inoculum. DMSO was added in the maximum 
concentration used in tested compounds. To ensure that the method used was being 
correctly performed, it was used a quality control. Quality control (QC) consists in execute 
the same procedures with a reference strain, which has already an expected result. The QC 
used was Candida parapsilosis ATCC 22019 with FLC. Plates were incubated for 24h to 
48h, at 35ºC for Candida and Aspergillus species, and for five days, at 28ºC, for 
dermatophytes. MICs were interpreted regarding those concentrations that showed no 
growth compared with the growth control well; except for the QC with FLC, where the MIC 
should be interpreted as that concentration which showed a 50% decrease in fungal growth 
compared with de GC. 
 
Evaluating the antibacterial activity of xanthones and chalcones 
Library of natural and synthetic compounds 
For this test were used the same compounds aforementioned (Fig. 24-38). 
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Microorganisms and media 
Concerning to the antibacterial activity, were used three different bacteria - 
Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa. The 
microorganisms were sub-cultured on Mueller-Hinton Agar, for 24h, at 35ºC, to ensure 
purity and viability. 
Mueller-Hinton Broth (MHB, Appendix B) was used. Minimum inhibitory 
concentrations (MICs) were obtained for all of the microorganisms, according to the 
National Committee for Clinical Laboratory Standards Institute M7-A9 and M100-S1748-49. 
 
 
Antifungal susceptibility testing by broth microdilution48-49 
All the aforementioned compounds were dissolved in dimethyl sulfoxide (DMSO), 
initial concentration of 25.6 mg/mL, diluted in MHB and tested from 1024 µg/mL to 128 
µg/mL on plates. 
The method used of broth microdilution was exactly the same that was mentioned for 
the antifungal activity assessment. The QC used was Pseudomonas aeruginosa ATCC 27853 
with Gentamicin. Plates were incubated for 24h at 35ºC and MICs were interpreted as those 
concentrations which showed no growth compared with the growth control well. 
 
Assessment of the effect of thioxanthones and chalcones in efflux pumps 
inhibition 
Library of natural and synthetic compounds 
For this test were used eight compounds, 7 thioxanthones and 1 chalcone (Fig. 39-46). 
These compounds were diluted in DMSO or in distilled water (Appendix A). 
 
 
Thioxanthones 
 
Figure 39 – Chemical structure of TXA1 
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Figure 40 – Chemical structure of TXA1.HCl 
 
 
Figure 41 – Chemical structure of TX34 
 
Figure 42 – Chemical structure of TX34.HCl 
 
 
Figure 43 – Chemical structure of TX53 
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Figure 44 – Chemical structure of TX128 
 
 
 
 
 
 
Figure 45 – Chemical structure of TXOMe 
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Chalcones 
 
Figure 46 – Chemical structure of FP10 
 
 
Microorganisms and media 
Four Candida strains (two C. albicans, DSY 294 and DSY 296, and two C. glabrata, 
DSY 562 and DSY 565) were used in the present study, including two azole-susceptibility 
strains (DSY 294 and DSY 562) and two azole-resistant strains (DSY 296 and DSY 565). 
These strains were kindly provided by Prof. D. Sanglard (University of Lausanne, Lausanne, 
Switzerland). MICs of each compound were obtained for all of the strains according to the 
National Committee for Clinical Laboratory Standards Institute M27-A3 and M27-S3 
protocols45, 47, as described. 
 
 
Antifungal agents 
The commercial antifungals used over this work, to evaluate the susceptibility of 
Candida strains, were obtained from Sigma-Aldrich: Fluconazole, Itraconazole, 
Voriconazole and Posaconazole. These drugs were dissolved in distilled water or dimethyl 
sulfoxide (DMSO) according to NCCLS protocols, and were diluted in RPMI 1640. 
 
 
Efflux pumps inhibitors 
To test the inhibition of the efflux pumps were used known EPIs (Fig. 21-23): 
Verapamil hydrochloride, Amiodarone and Sodium azide, from Sigma Aldrich. 
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Efflux pump inhibition testing by broth microdilution45, 47 
This assay was also accomplished using the broth microdilution already described for 
yeasts. It was also performed in a 96-well microtiter plates, using a SC, a GC and a QC to 
validate the results obtained. 24h cultures of C. albicans and C. glabrata strains were used 
to obtain the inoculum with 0.5 McFarland standard at 530 nm wavelength. This procedure 
has yielded a yeast stock suspension of 1 x 106 to 5 x 106 cells/mL. A working suspension was 
made by 1:50 dilution followed by a 1:20 dilution of the stock suspension to obtain the 
twofold inoculum (1 x 103 to 5 x 103 CFU/mL). 100 µL of this suspension (1:1 dilution) was 
added to each well to give a final density of 0.5 x 103 to 2.5 x 103 CFU/mL. In the first two 
rows, a 100 µL volume of yeast suspension, a 50 µL volume of RMPI 1640 containing a 
fourfold concentration of FLC (1 µg/mL -128 µg/mL) and a 50 µL volume of medium 
containing a fourfold concentration of each compound tested in different concentrations, 
was added to a series of wells. From third to sixth row, a 100 µL volume of RMPI 1640 
containing a twofold concentration of FLC was added to a 100 µL of a mixture of yeast and 
compound tested in different concentrations, placed in contact 1 hour and 2 hours before. 
In the seventh row, it was only added the FLC to the culture to evaluate if there was or not 
a decrease in the MIC. 
There was also a well to test each individual compound, to confirm that these 
compounds by themselves were not responsible by the growth inhibition. Plates were 
incubated for 24h at 35ºC and MICs were interpreted as those concentrations which showed 
a 50% decrease in growth compared with the growth control well, due to the trailing effect 
of azoles. 
 
 
Drug interaction evaluation 
In vitro drug interactions were evaluated with a two dimensional, two agent broth 
microdilution checkerboard technique, to understand the interaction between the azoles 
and VRP, AMD, AZD and the compounds from CEQUIMED-UP. 
  
34 
 
 
Chapter III 
Results and 
Discussion 
  
35 
Results and Discussion 
Evaluating the antifungal activity of xanthones and chalcones 
The results obtained on the evaluation of the antifungal activity of 10 xanthones and 
5 chalcones, tested against C. albicans, A. fumigatus and T. rubrum, are present in Table 
4. 
Table 4 – Antifungal effect of the compounds tested 
Compound C. albicans A. fumigatus T. rubrum 
Xanthones 
X2ADF-RS NI NI NI 
X2ADF-SR NI NI NI 
XEVOL-L NI 
Growth inhibition 
at 512-1024 µg/mL 
concentrations 
Growth inhibition 
at 512-1024 µg/mL 
concentrations 
XEVOL-D NI NI NI 
XEGOL-1D NI NI NI 
XEGOL-1L NI NI NI 
XEGOL-2D NI NI NI 
XEGOL-2L NI NI NI 
XEA-1S NI NI NI 
XEA-1R NI NI NI 
Chalcones 
PB3 NI NI NI 
PB4 NI NI NI 
PB6 NI NI NI 
PB16 NI NI NI 
PB17 NI NI NI 
NI – No growth inhibition 
Foremost, concerning to the antifungal activity exhibited by the compounds from 
CEQUIMED-UP – xanthones and chalcones – almost none of the compounds tested has 
shown results that must be considered. The exception is XEVOL-L, a xanthone that seems 
to have some effect against A. fumigatus and T. rubrum between 512 µg/mL and 1024 
µg/mL concentrations.  
Such as many compounds existing in nature, XEVOL-L and XEVOL-D are 
enantiomers. In other words, the two molecules are related as object and mirror image. 
Usually, the chiral molecules contain an atom that is connected to four different substituent 
groups, which is called an asymmetric atom or a stereocenter50. The different biological and 
pharmacological activities of enantiomers, amongst the advances in synthetic and analytical 
methodologies allowed to increase the interest in this field38. Therefore, despite the 
similarity between the two molecules, only XEVOL-L was able to induce some reduction in 
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fungal growth, possibly due to its facility to bind on binding site. This result shows that has 
occurred enantioselectivity, because only one of these two molecules has showed some 
antifungal effect.  
Concerning to XEVOL-L, , which has demonstrated some fungal growth inhibition in 
filamentous fungi, but no antifungal activity against yeasts, it would be also interesting to 
suppose that this is due to the presence of chitin in filamentous fungi cell wall. However, 
this mechanism should be studied and evaluated to understand exactly the reason why it 
occurs. 
According to a study developed by Pinto et al., 2014, the dermatophytes were found 
to be more sensitive to 8 of 16 active compounds tested, than Candida and bacteria species51. 
A study performed by CEQUIMED-UP, Faculty of Pharmacy, University of Porto15, 
has tested some synthetic and naturally occurring xanthone derivatives to evaluate the 
influence of the nature and position of the substituents on structure-activity relationship 
(SAR) of antifungal xanthones and to investigate the effect of the most active compounds 
on sterol biosynthesis. From 27 simple oxygenated xanthones, their antifungal profile 
suggests that hydroxyl groups are important for activity. However, because of some 
limitations concerning biosynthesis and synthetic methods, the pattern of oxygenation is 
frequently restricted to positions 1, 3, 5, 6 for simple oxygenated and prenylated xanthones, 
and to 1, 4, 8 for polycyclic and dehydroxanthones.15. 
Hereafter, it is important to apply some molecular modifications to improve the 
potential antifungal activity of this compound and to understand exactly how the compound 
is recognized in the binding site. After further studies to uncover the molecular mechanism 
of action of these compounds, if the target will be elucidated, a door it will be open for design 
of new and more potent molecules. 
 
Evaluating the antibacterial activity of xanthones and chalcones 
The antibacterial activity was evaluated using 15 xanthones and chalcones, against 
three different bacteria – E. coli, S. aureus and P. aeruginosa. The selection of these 
bacteria was made to observe if there was some selectivity for a particular group, once E. 
coli is a Gram negative bacteria, P. aeruginosa is a Gram negative bacteria resistant to most 
antibiotics, and S. aureus is a Gram positive bacteria. 
However, no antimicrobial activity was observed at 1024 µg/mL, the higher 
concentration tested. 
Several previous studies, such as Pinto et al., 2011, have reported some xanthones as 
important antifungal agents, and it seemed interesting to test this class of compounds 
against bacteria also, to evaluate its action spectrum15. 
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In some studies performed with xanthones and many other natural compounds, 
antibacterial activity has showed a variable spectrum and potency depending on the 
bacteria. Some of these compounds showed to be selective to Gram positive bacteria, such 
as S. aureus, being inactive for Gram negative bacteria51-52. In general, S. aureus showed 
higher sensitivity than E. coli and P. aeruginosa, which could be related to the presence of 
an outer membrane in Gram negative bacteria or even to the cell wall composition. 
However, along this study, the tested compounds showed no activity, even for Gram positive 
bacteria. 
 
Assessment of the effect of thioxanthones and chalcones in efflux pump 
inhibition 
In order to evaluate the capability of some compounds to inhibit efflux pumps, known 
as a mechanism of resistance, were tested several azoles (fluconazole, itraconazole, 
voriconazole and posaconazole) against four Candida strains (showed in Table 5), to 
understand which were sensitive or resistant to this group of antifungals. To furthermore 
test the effect in EPIs, FLC was the only antifungal used against the resistant strains. 
DSY 296 and DSY 565 showed MIC values representing resistance to all the azoles 
tested, a feature frequently associated with cross resistance to these antifungals5, 35. The 
overexpression of CDR genes confers resistance to different azoles, while overexpression of 
MDR1 seems to confer specific resistance to FLC14. 
Table 5 – Candida strains used and their antifungal susceptibility to azoles 
Strain 
Name 
MIC (categorization according breakpoints)45, 47 
Fluconazole Itraconazole Voriconazole Posaconazole 
C. albicans 
DSY 294 
4 µg/mL 
(Sensitive) 
2 µg/mL 
(Resistant) 
0.03 µg/mL 
(Sensitive) 
1 µg/mL 
(No Breakpoints) 
C. albicans 
DSY 296 
≥ 128 µg/mL 
(Resistant) 
4 µg/mL 
(Resistant) 
2 µg/mL 
(Sensitive Dose 
Dependent) 
4 µg/mL 
(No Breakpoints) 
C. glabrata 
DSY 562 
8 µg/mL 
(Sensitive) 
4 µg/mL 
(Resistant) 
0.25 µg/mL 
(Sensitive) 
4 µg/mL 
(No Breakpoints) 
C. glabrata 
DSY 565 
≥ 128 µg/mL 
(Resistant) 
≥ 16 µg/mL 
(Resistant) 
4 µg/mL 
(Resistant) 
≥ 32 µg/mL 
(No Breakpoints) 
 
 
Regarding to what was described in section 1. Introduction - Efflux pumps in 
resistance to azoles, DSY 29634 and DSY 56535 have acquired resistance to FLC due to their 
overexpression of efflux pumps (CDR1, CDR2 and MDR1 for C. albicans, and CgCdr1 and 
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CgCdr2 for C. glabrata). These strains, kindly provided by D. Sanglard, were previously 
investigated and compared by other groups research, and it was concluded, for example, 
that the transcription factor TAC1 in the resistant isolate DSY296 contains a mutation (not 
present in sensitive strain DSY294), which results in high expression of CDR1 and CDR234. 
To verify if the resistance to azoles exhibited by DSY 296 and DSY 565, was due to an 
increase of the drug efflux, mediated by the higher expression of the genes that regulate 
efflux pumps, were first tested some compounds with known inhibitory efflux pump 
activity. The EPIs were used in sub inhibitory concentrations, in order to guarantee that 
EPIs by themselves were not responsible for inhibit fungal growth (Table 6). 
 
Table 6 - Determination of the MIC of the commercial EPIs  
Compound 
MIC – pH 5.0 MIC – pH 7.0 
DSY 296 DSY 565 DSY 296 DSY 565 
VRP 250 µM 500 µM 500 µM 1000 µM 
AMD 25 µM 25 µM 500 µM 1000 µM 
AZD 100 µM 100 µM 500 µM 1000 µM 
 
 
 
Based on a study developed by Gamarra et al., 2010, it was decided to evaluate the 
effect of the FLC and commercial EPIs combination, at pH 7.0 and pH 5.0. According to 
that study, the MIC values for AMD against C. albicans showed significant variation as a 
function of pH with the lowest values observed at pH 5.0 for all strains examined43. In fact, 
it was observed that if the pH of the medium decreases, in general, there is a reduction in 
the FLC MIC, as well as the concentration of the commercial compound necessary to use in 
association (Table 7). 
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Table 7 – FLC MIC in combination with commercial EPIs 
Compound 
pH 5.0 pH 7.o 
DSY 296 DSY 565 DSY 296 DSY 565 
Fluconazole 
(FLC) FLC  128 µg/Ml 
Verapamil 
(VRP) 
VRP 100 µM + 
FLC 128 µg/mL 
VRP 100 µM + 
FLC 128 µg/mL 
VRP 100 µM + 
FLC 64 µg/mL 
VRP 100 µM + 
FLC 128 µg/mL 
Amiodarone 
(AMD) 
AMD 15 µM +  
FLC 8 µg/mL 
AMD 15 µM +  
FLC 8 µg/mL 
AMD 100 µM + 
FLC 128 µg/mL 
AMD 100 µM + 
FLC 128 µg/mL 
Sodium Azide 
(AZD) 
AZD 50 µM +  
FLC 128 µg/mL 
AZD 50 µM +  
FLC 128 µg/mL 
AZD 100 µM +  
FLC 128 µg/mL 
AZD 100 µM + 
FLC 128 µg/mL 
 
 
For AMD, a pH 5.0 medium allows to reduce the concentration of the compound from 
100 µM to 15 µM, and FLC is able to inhibit fungal growth at 8 µg/mL, instead of 128 µg/mL 
(Fig. 47). For AZD, there is a decrease of its concentration from 100 µM to 50 µM, but the 
FLC concentration needed stills the same. 
As aforementioned, this result for AMD probably is due to the capacity of this 
compound to induce calcium stress and modify the calcineurin pathway regulation, 
changing the tolerance to antifungal agents43. 
The use of lower concentrations to obtain the inhibition of fungal growth could help 
to decrease the probability of occurring side effects and toxicity to the human host. 
 
 
Figure 47 - Influence of the pH of the medium in FLC MIC 
 
 
Toward the inhibition of efflux pumps, responsible for the resistance to antifungals, it 
was possible to observe the potential of AMD as EPI, at pH 5.0. In contrast, for pH 7.0 
medium, none of the EPIs were able to revert the phenotype of resistance of these strains. 
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A study developed by Pina-Vaz, C., 2000, using different strains of C. albicans, C. 
glabrata and C. krusei, showed significant reduction of FLC MIC when associated to VRP, 
allowing the reversal of the resistant (R) phenotype to sensitive (S) phenotype in 6 of the 8 
strains tested53. However, this was not observed along this work, probably because it was 
performed with different strains with other features. 
For pathogenic fungi, ambient pH is important because it determines the ability of the 
pathogen to successfully colonize and invade the targeted host. Therefore, modulation of 
the pH may induce alterations in the way pathogenic fungi act in the host, as well as it may 
affect the efflux pumps function and the secretion of pathogenicity factors54. 
During the period of time of this dissertation, the study was performed only with pH 
7.0 medium. Further studies are needed to assess the feasibility of administering antifungal 
drugs with EPIs, in an action site with an acidic pH, lower than 7.0. 
Using EPIs already known, it was found a method to then test the samples from 
CEQUIMED-UP, employing new compounds (Fig.39-46). Thioxanthones and chalcones 
were tested in order to assess their capacity to inhibit antifungal mechanisms of resistance. 
Table 8 represents the MIC for these compounds when alone, in order to find the sub-
inhibitory concentration that should be used when in combination with FLC. 
Table 8 – Determination of the MIC of thioxanthones and chalcones 
Compound MIC - pH 7.0 
TXA1 32 µg/mL 
TXA1.HCl 32 µg/mL 
TX34 > 128 µg/mL 
TX34.HCl > 128 µg/mL 
TX53 > 128 µg/mL 
TX128 > 128 µg/mL 
TXOMe > 128 µg/mL 
FP10 > 128 µg/mL 
 
 
 
TXA1 and TXA1.HCl seems to possess some antifungal activity by themselves, since 
their MICs were 32 µg/mL for both. Further studies are also needed to uncover the exact 
mechanism of action of this type of xanthones against DSY 296 and DSY 565 and other 
fungi. 
Table 9 indicates the result for the in vitro activity of FLC alone and in combination 
with the compounds tested. 
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Table 9 – FLC MIC in presence of tioxanthones and chalcones 
MIC (µg/mL) – pH 7.0 
Strain FLC 
FLC + 
TXA1 
16µg/mL 
FLC + 
TXA1.HCl 
16µg/mL 
FLC + 
TX34 
128µg/mL 
FLC + 
TX34.HCl 
128µg/mL 
FLC + 
TX53 
128µg/mL 
FLC + 
TX128 
128µg/mL 
FLC + 
TXOMe 
128µg/mL 
FLC + FP10 
128µg/mL 
DSY 
296 128 64 64 64 128 64 128 128 128 
DSY 
565 128 64 64 64 128 64 128 128 128 
 
 
Associating FLC with one of these EPIs, MIC reduced only from 128 µg/mL (FLC 
alone) to 64 µg/mL. In some cases, the FLC MIC remained the same, with EPI or not. 
Thus, it can be concluded that none of these thioxanthones was able to inhibit this 
mechanism of resistance, when associated to FLC. Hereafter, it should be interesting to test 
the same thioxanthones in different conditions – different azoles, different pH or different 
fungi, or bacteria. 
It was expected some activity of FP10, once it has an aliphatic chain in the ortho-
position of the phenyl residue adjacent to the C=O group. This feature seems to contribute 
significantly to increase its inhibitory activity in tumor cell lines, described by Neves et 
al.,201237. Furthermore, the pharmacological activity of chalcones may be also related to 
the presence, number and position of OH and MeO groups in both A and B rings37. For these 
reasons, this compound was tested against fungi to understand if its mechanism was able 
to inhibit the fungal growth also. 
Ultimately, along this work, both the evaluation of the antifungal activity and the 
assessment of the effect of a library of compounds in efflux pump inhibition, were 
performed using an in vitro susceptibility testing by broth microdilution, according to the 
NCCLS Institute M27-A3, M27-S3, M38-A2 and M7-A9 protocols. The main objective of all 
in vitro susceptibility testing, antifungal or antibacterial, is to predict the likely impact of 
administration of the tested agent on the outcome of infection caused by the tested 
organism or similar organisms55.This is a simple visual method that allows observing the 
fungal growth. For azoles, there is a prominent trailing effect, which results in growth at all 
drug concentrations regardless of susceptibility. Therefore, determinations of the MIC 
depends on a difficult visual assessment of 50 to 80% reduction in growth relative to the 
drug-free control12. 
Hence, there is a need for more rapid test procedures or “real time” antifungal 
susceptibility testing14. Moreover, not always the test conditions through the broth 
microdilution are the same, and cause differences, being necessary to use methods of 
detection of the fungal growth that allows more accurate and reproducible results. 
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Concerning the screening of antifungal activity, flow cytometric methods have been 
adapted for testing some antifungals against Candida spp. This approach uses a standard 
flow cytometer and fluorescent DNA binding dyes to detect fungal cell damage following 
exposure to an antifungal agent. The flow cytometric method produces results within 6h 
that agree very well with MICs determined by the M27 reference method56. 
In addition, to evaluate the efflux pump inhibition, it is possible to appraise the 
intracellular concentration of FLC by liquid chromatography-tandem mass spectrometry 
method, described by Sun et al.57, to measure the Rh123 uptake and glucose-induced efflux, 
or to measure the expression of CDR1 using RT-PCR analysis11. 
A study developed by a group research of University of Otago, used two novel 
strategies to identify new candidate compounds that block efflux pumps in fungi. In this 
study, the yeast cell is incubated with a fluorescent substrate and glucose, allowing to 
quantify pump activity. They used control cells, without efflux pumps, producing high 
fluorescence; resistant yeast cells with ABC efflux pumps, emitting low fluorescence; and 
resistant yeast cells with EPIs that have also produced high fluorescence58. 
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Conclusion and Future Work 
Concerning to the antimicrobial activity of all compounds tested, only XEVOL-L has 
showed some antifungal activity against filamentous fungi, such as A. fumigatus and T. 
rubrum. None of the compounds tested have exhibited some antibacterial potential, in 
contrast to what is described for many natural compounds. Moreover, related to the efflux 
pump inhibition, none of the compounds have revealed some activity when associated to 
FLC. Only AMD and AZD seems to provide some advantage when associated to FLC, once 
the concentration of the commercial EPIs, at pH 5.0, showed a substantial reduction, and 
AMD allowed to decrease FLC MIC too. 
Furthermore, it would be interesting to test more compounds from the same nature, 
as long as their chemical diversity and the possibility to be synthesized easily, could allow 
to find other compounds with potential to interact with some important targets in bacteria 
and fungi. Using other azoles and other resistant strains, such as C. krusei strains, which 
exhibit also resistance to azoles, could be also a challenging question to explore. According 
to the results obtained in the susceptibility testing done with DSY 294, DSY 296, DSY 562 
and DSY 565, all these strains were resistant to itraconazole, so it would be interesting to 
test this particular azole against these 4 strains. 
Additionally, it would be important to prove the potential of AMD to reverse 
antifungal resistance by inhibition of efflux pumps or, eventually, as antifungal agent, once 
there are some studies referring its antifungal potential. The results obtained at pH 5.0, with 
AMD and AZD, can lead to interrogate and search the exact mechanism whereby the pH 
affect the efflux pump activity, and how it is possible for compounds to achieve the site of 
action with a low pH that improve its activity. 
Moreover, despite the use of the susceptibility testing by broth microdilution, could 
be used flow cytometric methods to evaluate the activity of some antifungals against fungi. 
In addition, to evaluate the efflux pump inhibition, it is possible to use other techniques 
such as liquid chromatography-tandem mass spectrometry to measure the concentration of 
FLC, or RT-PCR analysis to assess the expression of CDR1. 
With this work is possible to say that it was given an interesting contribution to deeper 
knowledge, concerning the research area of biological activities of chalcones and xanthones 
derivatives. Although many compounds have not expressed antifungal or efflux pump 
inhibitory activity, these data may be relevant for later studies of SAR to be made for these 
families of compounds, as well as paving the way for design new and more potent molecules. 
All this study suggests that there are several possibilities to revert the phenotype of 
resistance to the antifungals, because this is a real healthcare problem which requires 
concern and attention when treating these conditions. This issue is also responsible for 
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increasing the healthcare costs in hospitals, as well as in the community. Beyond all these 
factors, the conditions leading to clinical resistance should be considered while managing 
invasive fungal infections in patients with some of the predisposing factors mentioned over 
the work. 
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Appendix 
 
Appendix A – Compounds from CEQUIMED-UP 
 
Figure Compound Molecular Weight (g/mol) Solvent 
24 X2ADF-RS 465.51 DMSO 
25 X2ADF-SR 465.51 DMSO 
26 XEVOL-L 355.39 DMSO 
27 XEVOL-D 355.39 DMSO 
28 XEGOL-1D 389.41 DMSO 
29 XEGOL-1L 389.41 DMSO 
30 XEGOL-2D 389.41 DMSO 
31 XEGOL-2L 389.41 DMSO 
32 XEA-1S 387.44 DMSO 
33 XEA-1R 387.44 DMSO 
34 PB3 302.75 DMSO 
35 PB4 337.20 DMSO 
36 PB6 337.20 DMSO 
37 PB16 353.19 DMSO 
38 PB17 353.19 DMSO 
39 TXA1 384 DMSO 
40 TXA1.HCl 419.5 Water 
41 TX34 353.5 DMSO 
42 TX34.HCl 389 Water 
43 TX53 396.5 DMSO 
44 TX128 421.5 DMSO 
45 TXOMe 300.37 DMSO 
46 FP10 442.5 DMSO 
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Appendix B – Medium composition 
 
RPMI 1640 Medium 
 Concentration Mass Solvent Final Volume Final pH 
RPMI 1640 
(Biochrom) 
5.2 g/500 mL 10.4 g 
Distilled 
Water 
1000 mL 7 ± 0.2 M1254 
MOPS 
(Sigma Life 
Science) 
17.27 g/500 
mL 
34.54 g 
 
Powdered medium should be dissolved in 900 mL distilled H2O and MOPS (final 
concentration of 0.165 mol/L) added. While stirring, the pH must be adjusted to 7,0 ± 0,2 
at 25ºC using 1 mol/L sodium hydroxide. Add additional water to bring medium to a final 
volume of 1 L. Filter sterilize and store at 4 °C until use. 
 
 
 
 
Mueller Hinton Broth (BD Difco) 
 Concentration Mass Solvent Final Volume Final pH 
Extrait de 
Bouef 
22.0 g/1000 
mL 
3.0 g 
Water 1000 mL 7.3 ± 0.1 
Hidrolysat 
Acide de 
Caséine 
17,5 g 
Fécule 1,5 g 
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Opportunistic bacterial and fungal infections have increased due to the growing number of 
immunocompromised patients. Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia 
coli, are the most commonly involved bacteria [1]. Although fungal infections contribute substantially 
to human morbidity and mortality, the impact of these diseases in human health is not widely 
appreciated. Candida and Aspergillus species are the most frequent nosocomial fungal pathogens 
responsible for systemic infections which kill about one and a half million people every year [2]. 
Nevertheless, the most common fungal diseases in humans are superficial infections, which affect 
approximately 25% of the world's population. They are predominantly caused by dermatophytes and 
affect also healthy persons with a considerable impact on patient’s life quality [3]. 
The main challenge in developing antifungal drugs is related to the similarity between fungi 
and their hosts. Antifungal drugs often exhibit therapeutic limitations with fungistatic mechanism of 
action, high toxicity, many drug interactions, insufficient bioavailability and development of 
resistance or innate resistance [4]. Thus, it is imperative to continue the discovery and development 
of new antimicrobial drugs, more effective and less toxic than those already in use, especially those 
with new mechanisms of action. 
Based on these precedents, this project for the thesis for Masters in Pharmaceutical Chemistry 
aims to evaluate the antimicrobial activity of a library of xanthonic derivatives, especially chiral 
compounds, against clinically relevant bacteria and fungi (Candida, Aspergillus and dermatophyte 
species) using the broth microdilution method by Clinical and Laboratory Standards Institute. 
Considering the battery of compounds available, it will be expected the possibility of the 
establishment of some structure-activity relationships (SARs). For the compounds showing 
antifungal activity some mechanisms of action will be evaluated. 
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